John W.
Hanna

Every year, around 45,000 Americans receive an organ transplant. Every single one of them will spend the rest of their life wondering if their body is quietly trying to reject it. For decades, the only way to know for certain involved a needle, a tissue sample, and a wait. John Hanna is in the business of ending that.

As President and CEO of CareDx, Hanna leads the company behind AlloSure - a liquid biopsy test that detects transplant rejection risk from a blood draw by measuring donor-derived cell-free DNA. The science is elegant. The commercial challenge is harder: convincing cardiologists, nephrologists, and transplant coordinators who've been doing things one way for thirty years that a blood test can replace what their hands have always done.

Hanna took the CareDx chair in April 2024, stepping in to sharpen a company that had the right technology but needed a tighter commercial story. He arrived with credentials that read less like a biotech CEO and more like someone who'd been specifically assembled for this problem: a decade at Veracyte learning how to sell molecular diagnostics into skeptical clinical audiences, two years at Apton Biosystems learning how to lead a platform-stage NGS company, and a stint at Humana that gave him something most diagnostics executives simply don't have - a front-row seat to how payers actually think.

When Hanna arrived at CareDx, the company was essentially a one-test story. AlloSure was the product. AlloSure was the pitch. That was the limit of the conversation a CareDx sales rep could have with a transplant center.

Hanna's rewrite goes deeper. The new commercial motion is what he calls "solution selling" - entering transplant centers not with a brochure for a single test but with an integrated offer: molecular diagnostics, workflow software, quality reporting tools, specialty pharmacy services, and EMR integration through EPIC. The idea is to become operationally indispensable. Not the vendor that runs one panel. The partner that runs the floor.

CareDx now operates across three distinct business segments: a lab products division selling HLA typing kits, a software and patient solutions division, and the genomics portfolio anchored by AlloSure. The three-segment architecture isn't just a revenue diversification story - it's a flywheel. Each segment reinforces the other's stickiness with transplant centers.

The AI layer - AlloSure Plus - sits on top of all of it. The platform pulls genomic results from AlloSure and layers in EMR-derived clinical variables to generate a rejection risk score. Integrated directly into Epic Aura, it's designed to remove the clinician's cognitive burden. The test result doesn't just appear. It arrives in context, with an interpretation pre-built into the workflow they're already using.

At the 2025 World Transplant Congress, CareDx showed up with 40+ abstracts and 16 oral presentations. That's not a marketing budget story. That's a company with enough clinical data in the pipeline that it could fill the program of the field's most important annual meeting.

Hanna graduated from Hampden-Sydney College in 2001 with a degree in political science. Not biology. Not chemistry. Not the standard-issue pre-med transcript you'd expect from the future CEO of a molecular diagnostics company. He came into the workforce thinking in terms of persuasion, systems, and constituencies - which turns out to be exactly the right mental model for selling genomic tests to skeptical clinicians.

He started at IBM in sales and business development. Then moved to Humana, where he learned healthcare from the payer side - the side that decides whether innovations actually get paid for. Most life sciences executives spend careers wondering why their brilliant new technology can't get reimbursed. Hanna got to see that machinery from the inside before he ever worked in diagnostics.

The pivot came in 2011 when he joined Veracyte, then a young oncology diagnostics company focused on thyroid cancer. Over the next decade he worked through nearly every commercial role the company had - VP of Marketing, General Manager for endocrinology, breast cancer, and lymphoma, then Chief Commercial Officer. He was there for the company's growth from a single-indication business into a multi-cancer genomics platform. He built the revenue engine. He learned how to change clinical behavior at scale.

In 2021 he went smaller by choice: CEO of Apton Biosystems, a startup building a high-throughput next-generation sequencing platform for liquid biopsy. When Pacific Biosciences acquired Apton in August 2023, Hanna transitioned to VP of Corporate Development - his first sustained exposure to M&A strategy from the acquirer's perspective. He spent less than a year there before CareDx called.